Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation

In recent years, emerging tools for targeting tumor cells via the immune system have shifted oncologists’ focus away from cytotoxic chemicals and onto immunotherapy. Almost all of the functions of the immune system may have therapeutic implications, and many have already been widely studied in experimental models and in humans. Among them, antibody-dependent cell-mediated cytotoxicity [ADCC] appears to be a promising field of investigation.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BbPvAK
via IFTTT